The Edwards Lifesciences Corp (EW) Cut to “Buy” at Vetr Inc.

The Edwards Lifesciences Corp (EW) Cut to “Buy” at Vetr Inc.

Several other equities research analysts have also commented on the company. Jefferies Group LLC restated a “buy” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday, April 26th. Royal Bank of Canada upped their price target on Edwards Lifesciences Corp from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 26th. Stifel Nicolaus upped their price target on Edwards Lifesciences Corp from $114.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Cowen and Company reiterated an “outperform” rating and issued a $120.00 target price on shares of Edwards Lifesciences Corp in a research note on Tuesday, March 28th. Finally, Evercore ISI upgraded Edwards Lifesciences Corp from an “in-line” rating to an “outperform” rating and increased their target price for the company from $98.50 to $110.00 in a research note on Monday, March 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corp has an average rating of “Buy” and an average target price of $120.29.

Edwards Lifesciences Corp (NYSE:EW) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued on Monday, May 15th. They presently have a $124.67 target price on the medical research company’s stock. Vetr‘s target price suggests a potential upside of 6.05% from the stock’s current price.

Shares of Edwards Lifesciences Corp (EW) opened at 117.56 on Monday. Edwards Lifesciences Corp has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market capitalization of $24.66 billion, a P/E ratio of 39.08 and a beta of 0.53. The firm has a 50 day moving average price of $109.11 and a 200-day moving average price of $96.42.

In other Edwards Lifesciences Corp news, VP Patrick B. Verguet sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $114.88, for a total value of $1,148,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael A. Mussallem sold 49,100 shares of the business’s stock in a transaction dated Friday, April 28th. The stock was sold at an average price of $109.78, for a total value of $5,390,198.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 251,321 shares of company stock valued at $27,139,313. Insiders own 2.37% of the company’s stock. Hedge funds have recently made changes to their positions in the company. Seven Bridges Advisors LLC raised its position in Edwards Lifesciences Corp by 1.0% in the third quarter. Seven Bridges Advisors LLC now owns 3,536 shares of the medical research company’s stock worth $426,000 after buying an additional 34 shares during the last quarter. Quadrant Capital Group LLC raised its position in Edwards Lifesciences Corp by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the last quarter. National Asset Management Inc. raised its position in Edwards Lifesciences Corp by 1.0% in the third quarter. National Asset Management Inc. now owns 4,425 shares of the medical research company’s stock worth $534,000 after buying an additional 45 shares during the last quarter. Rehmann Capital Advisory Group raised its position in Edwards Lifesciences Corp by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Edwards Lifesciences Corp by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,257 shares of the medical research company’s stock worth $1,148,000 after buying an additional 99 shares during the last quarter. 83.99% of the stock is owned by institutional investors.

Edwards Lifesciences Corp Company Profile Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “EW”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view Vetr’s full report, visit Vetr’s official website.

Related posts

Leave a Comment